FDA Evaluating MolecularHealth's MASE for Analyzing Post-Market Drug Safety
February 15, 2012
FDA Evaluating MolecularHealth's MASE for Analyzing Post-Market Drug Safety
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- SV Bio Seeks Foothold in NGS-Based Clinical Dx Market with Proprietary Interpretation Pipeline
January 18, 2013 / BioInform - New Players, Clinical Applications, and the Lure of Commercialization among 2012 Bioinformatics Trends
January 4, 2013 / BioInform - People in the News: Larry Lesko
March 14, 2012 / Pharmacogenomics Reporter - Life Biosystems Developing In Silico Toolkit for Personalizing Oncology Therapy
April 15, 2011 / BioInform - Vermillion Sends Quest Notice of Default Alleging Breach of Strategic Alliance Agreement
May 24, 2013 / ProteoMonitor